Here are the 424B prospectus supplements from HNO International Inc (HNOI) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow HNOI and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full HNOI filings page.
HNO International, Inc. is registering up to 32,570,000 shares of common stock for resale by existing investors rather than issuing shares directly to the public. This includes up to 25,500,000 shares tied to a $30,000,000 equity purchase agreement with Lambda Ventures and additional shares underlying previously issued convertible notes and warrants.
Under the Lambda facility, HNO may sell stock over 24 months at 80% of the lowest traded price during specified periods, subject to a 4.99% ownership cap for Lambda. Four unsecured convertible notes totaling $327,500 convert at the lesser of $0.25 or 60% of the lowest traded price before conversion and are paired with warrants for 1,540,000 shares at $0.25.
The company reports a net loss of $6,615,496 for the year ended October 31, 2025, an accumulated deficit of $52,633,084, and a working capital deficit of $2,613,968 as of April 30, 2026, leading to substantial doubt about its ability to continue as a going concern. Revenue to date is minimal and its flagship hydrogen project in Katy, Texas is not yet operational. The stock trades on the OTCQB at $0.11 per share as of July 27, 2026 and is subject to penny stock rules. The CEO holds super-voting preferred shares, giving him effective control and potentially deterring change-of-control transactions.